Aoli Wang
University of Science and Technology of China(CN)Anhui University(CN)Hefei University of Technology(CN)Chinese Academy of Sciences(CN)Hefei Institutes of Physical Science(CN)Cell Technology (China)(CN)Precision Research (United States)(US)Hefei Infectious Disease Hospital(CN)Hubei University of Technology(CN)
Publications by Year
Research Areas
Chronic Lymphocytic Leukemia Research, Chronic Myeloid Leukemia Treatments, PI3K/AKT/mTOR signaling in cancer, Acute Myeloid Leukemia Research, Gastrointestinal Tumor Research and Treatment
Most-Cited Works
- → Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity(2018)756 cited
- → Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders(2017)701 cited
- → Variation of gut microbiota caused by an imbalance diet is detrimental to bugs' survival(2021)79 cited
- → Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma(2014)75 cited
- → Discovery of N -(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC(2017)60 cited
- → Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor